Skip to Main Content

Paper Details

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i>-Mutant Non-Small Cell Lung Cancer.
Cancer Immunol Res
74
2018
BET, BET Bromodomain, BET bromodomain, JQ1, KRAS, KRAS-mutant tumors, Kras, NSCLC, PD-1, PD-1 antibody, T-helper type 1, Treg, Trp53, antitumor, hematologic malignancies, human, lung adenocarcinoma, lung adenocarcinomas, lung cancer, lung tumor, mice, mouse, non-small cell lung cancer, patients, regulatory T cells, solid malignancies, tumor, tumor-infiltrating T cells, tumor-infiltrating Tregs, tumors
Author NameAffiliation
Michaela BowdenDana-Farber Cancer Institute, Harvard Medical School
Elena IvanovaDana-Farber Cancer Institute, Harvard Medical School
Elena IvanovaBelfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
Elena IvanovaDana-Farber Cancer Institute, Harvard Medical School
Elena IvanovaBelfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
Peter S HammermanNovartis Institutes for Biomedical Research
Peter S HammermanNovartis Institutes for Biomedical Research
James E BradnerNovartis Institutes for Biomedical Research
John Alan DiehlHollings Cancer Center, Medical University of South Carolina
Adam J BassDana-Farber Cancer Institute, Harvard Medical School
  • 1 - 10

Datasets

Release 1.2